Gordon Ringold

Gordon Ringold is the founder of Maxygen, Inc. (founded in 1997) and SurroMed, Inc. (founded in 1997).
He held the title of Independent Director at Maxygen, Inc. from 2011 to 2013 and Chairman & Chief Executive Officer at SurroMed, Inc. from 1997 to 2005.
Dr. Ringold currently holds multiple positions.
He is the Executive Chairman & Chief Executive Officer at Alavita Pharmaceuticals, Inc. since 2000.
He is also the Chief Executive Officer & Director at Quadriga BioSciences, Inc., Chairman at Maverix Biomics, Inc., Director at Protein Metrics, Inc., Director at Okava Pharmaceuticals, Inc., Director at Rapafusyn Pharmaceuticals, and Managing Partner at Technogen Associates LP.
In his former positions, Dr. Ringold served as the Chief Executive Officer at Affymax Research Institute from 1995 to 2000.
He was also the Chairman of Nanoplex Technologies, Inc. and Director-Cancer Biology at Syntex Corp.
from 1986 to 2010.
Additionally, he held the role of Independent Director at Alexza Pharmaceuticals, Inc. from 2001 to 2016, Non-Executive Director at Oxonica Ltd. in 2005, Senior Director at the University of California, Santa Cruz from 2010 to 2013, Independent Director at Sagimet Biosciences, Inc. from 2009 to 2023, Independent Director at Ardelyx, Inc. from 2014 to 2021, and Independent Director at Apexigen, Inc. from 2020 to 2023.
Dr. Ringold's education includes an undergraduate degree from the University of California, Santa Cruz and a doctorate degree from the University of California, San Francisco.